Skip to main content

Table 2 Estimated probability of dual therapy discontinuation by cause (Kaplan-Meier survival analysis)

From: Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

  1 year 3 years 5 years
Overall 13.3 % 26.5 % 36.2 %
Virological failure 5.4 % 14.2 % 21.7 %
Toxicity 7.5 % 13.5 % 13.5 %